April 28, 2016 | Last night, a panel of advisors to the Food and Drug Administration voted 7 to 3, with 3 abstentions, that the agency should not approve eteplirsen, a drug for a Duchenne muscular dystrophy, a rare, deadly, muscle-destroying disease, developed by Sarepta, a Cambridge, Mass.-based biotechnology firm. (On another vote, which [...] Forbes